-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Overweight on BioMarin Pharmaceutical, Lowers Price Target to $86

Benzinga·11/04/2026 20:11:10
Listen to the news
JP Morgan analyst Jessica Fye maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and lowers the price target from $87 to $86.